for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

149.50USD

Change

0.75(+0.50%)

Volume

2,013,226

Today's Range

148.15

 - 

150.57

52 Week Range

126.10

 - 

150.57

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
148.75
Open
148.46
Volume
2,013,226
3M AVG Volume
133.38
Today's High
150.57
Today's Low
148.15
52 Week High
150.57
52 Week Low
126.10
Shares Out (MIL)
2,631.87
Market Cap (MIL)
391,491.00
Forward P/E
--
Dividend (Yield %)
2.55

Next Event

Dividend For JNJB34.SA - 3.8197 BRL

Latest Developments

More

Health Canada Approved Stelara For Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis

Janssen Says European Commission Approves Expanded Use Of Stelara For Treatment Of Paediatric Patients With Moderate To Severe Plaque Psoriasis

J&J Says Will Not Be Active Participant At FDA Hearing On Talc Testing Methods In Feb

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Contact Info

1 Johnson And Johnson Plz

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

2.06 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

76.5K

2018

81.6K

2019

82.1K

2020(E)

85.9K
EPS (USD)

2017

7.300

2018

8.180

2019

8.680

2020(E)

9.044
Price To Earnings (TTM)
26.72
Price To Sales (TTM)
4.77
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
24.01
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

J&J CEO questioned over stock sale ahead of story on asbestos in Baby Powder

Johnson & Johnson <JNJ.N> Chief Executive Alex Gorsky on Monday faced questions from plaintiffs lawyers over the timing of his sale of company stock, as he testified for the first time in a jury trial over allegations that the company's Baby Powder causes cancer.

J&J CEO to testify at trial for first time on Baby Powder risks

Johnson & Johnson Chief Executive Officer Alex Gorsky was set to be called as a witness on Monday in what would be his first appearance in a jury trial over allegations that the company's Baby Powder causes cancer.

J&J chief testifies he did not read all documents related to asbestos in talc

Johnson & Johnson Chief Executive Alex Gorsky told a jury Monday that he did not read all the internal company documents related to potential asbestos contamination in Johnson's Baby Powder.

J&J CEO to testify at trial for first time on Baby Powder risks

Johnson & Johnson Chief Executive Officer Alex Gorsky was set to be called as a witness on Monday in what would be his first appearance in a jury trial over allegations that the company's Baby Powder causes cancer.

J&J forecasts weak annual profit, misses revenue estimates

Johnson & Johnson on Wednesday forecast 2020 profit below Wall Street estimates and said increased competition for its off-patent treatments could somewhat limit growth in the top-earning pharmaceuticals unit.

Johnson & Johnson quarterly profit jumps 32%

Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.

Judge slashes $8 billion Risperdal award against Johnson & Johnson to $6.8 million

A Pennsylvania judge on Friday slashed to $6.8 million from $8 billion a punitive damages award against Johnson & Johnson to a man who said it failed to warn that boys using its antipsychotic drug Risperdal could grow breasts.

Judge slashes $8 bln Risperdal award against Johnson & Johnson to $6.8 mln

A Pennsylvania judge on Friday slashed to $6.8 million from $8 billion a punitive damages award against Johnson & Johnson for allegedly failing to warn men that they could grow breasts by using its antipsychotic drug Risperdal.

China regulator approves imports of J&J's Tremfya

China has approved imports of Johnson & Johnson's Tremfya (guselkumab), the National Medical Products Administration said in a notice on Friday.

J&J to buy remaining stake in Verb Surgical to strengthen digital surgery portfolio

Johnson & Johnson <JNJ.N> said on Friday it would acquire the remaining stake in Verb Surgical Inc, from Verily, Alphabet Inc's <GOOGL.O> life sciences division.

Britain's GSK seeks U.S approval for rival to J&J's multiple myeloma drug

GlaxoSmithKline <GSK.L> said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson <JNJ.N> and Genmab's Darzalex.

CORRECTED-BRIEF-Hubert Joly Reports Open Market Purchase Of 5,000 Common Shares of J&J At $141.3/Share

* J&J DIRECTOR HUBERT JOLY REPORTS OPEN MARKET PURCHASE OF 5,000 CO'S COMMON SHARES ON DEC 13 AT $141.2798/SHARE - SEC FILING Source (https://bit.ly/2M0tLQc) Further company coverage:

BeiGene cancer drug fails in study against AbbVie: J&J's Imbruvica

BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc. The results come merely a month after BeiGene scored a win with Brukinsa's approval to treat patients...

BeiGene drug fails main goal in late-stage study against AbbVie-J&J rival Imbruvica

BeiGene Ltd said on Monday a late-stage trial testing its recently approved cancer treatment Brukinsa did not meet the main goal of proving superior to Imbruvica, a rival medicine from Johnson & Johnson and AbbVie Inc.

J&J CEO spurns U.S. congressional hearing on carcinogens in talc products

Johnson & Johnson <JNJ.N> Chief Executive Officer Alex Gorsky has declined to appear at a U.S. congressional hearing set for Tuesday on the safety of the company's Baby Powder and other talc-based cosmetics.

J&J CEO Gorsky spurns U.S. congressional hearing on carcinogens in talc products

Johnson & Johnson Chief Executive Officer Alex Gorsky has declined to appear at a U.S. congressional hearing set for Tuesday on the safety of the company's Baby Powder and other talc-based cosmetics.

BRIEF-Argenx Receives First Milestone Payment Under Janssen Collaboration

* ARGENX ANNOUNCED ON SATURDAY RECEIPT OF FIRST MILESTONE PAYMENT UNDER JANSSEN COLLABORATION AND PROVIDES DATA UPDATE FROM PHASE 1 DOSE ESCALATION TRIAL OF CUSATUZUMAB IN ACUTE MYELOID LEUKEMIA AT ASH ANNUAL MEETING

FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.

FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.

Johnson & Johnson says new tests show no asbestos in Johnson's Baby Powder

Johnson & Johnson said on Tuesday that recent tests showed that Johnson's Baby Powder was free of asbestos, after U.S. Food and Drug Administration investigations reported trace amounts of the material in the product earlier this year.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up